E7777

DRUG4 trials

Conditions

Cutaneous T-cell LymphomaDLBCLDLBCL Arising From Follicular LymphomaDiffuse Large B Cell LymphomaEpithelial Ovarian CancerHigh-grade B-cell LymphomaPeripheral T-Cell LymphomaPeripheral T-cell Lymphoma

Phase 1

Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL

SuspendedNCT04855253

Masonic Cancer Center, University of MinnesotaDiffuse Large B Cell Lymphoma, DLBCL, DLBCL Arising From Follicular Lymphoma +1

Start: 2021-06-09End: 2026-12-31Target: 30Updated: 2026-01-15

T-regulatory Cell Depletion With E7777 Combined With Pembrolizumab in Recurrent or Metastatic Solid Tumors

Active, not recruitingNCT05200559

Alexander B Olawaiye, MDEpithelial Ovarian Cancer

Start: 2022-09-30End: 2030-12-31Updated: 2026-05-29

Phase 2

Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma

CompletedNCT02676778

Eisai Co., Ltd.Cutaneous T-cell Lymphoma, Peripheral T-cell Lymphoma

Start: 2016-03-28End: 2019-04-26Updated: 2021-07-15

Phase 3

A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma

WithdrawnNCT01355783

Eisai Inc.Peripheral T-Cell Lymphoma

Start: 2011-03-31End: 2014-11-30Updated: 2013-11-18

Related Papers

Depletion of T-regulatory cells by denileukin diftitox-cxdl (E7777) in combination with pembrolizumab in relapsed/refractory (r/r) gynecologic malignancies: Phase 1 study results.

Journal of Clinical Oncology2026-05-27

Phase I Clinical Trial of Pembrolizumab + and Denileukin diftitox in Patients with Recurrent Solid Tumors Shows Promising Results